AMRI Insider Trading Activity and SEC Form 4 Filings
AMRI insider trading summary
No open-market insider purchases or sales of Albany Molecular Research Inc (AMRI) have been reported on SEC Form 4 in the past 12 months.
Latest AMRI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 2, 2016 | Anthony J Maddaluna | Director | Buy | $25K (1,518 @ $16.46) |
| Nov 30, 2016 | Steven R Hagen | SVP Manufacturing & Pharmaceut | Sell | $150K (9,000 @ $16.71) |
| Nov 16, 2016 | Lori M. Henderson | SVP, Secretary & Gen Counsel | Sell | $102K (6,000 @ $17.00) |
| Nov 10, 2016 | Steven R Hagen | SVP Manufacturing & Pharmaceut | Sell | $13K (785 @ $16.79) |
| Aug 9, 2016 | Steven R Hagen | SVP Manufacturing & Pharmaceut | Sell | $21K (1,401 @ $15.29) |
| May 31, 2016 | Kevin Oconnor | Director | Sell | $72K (5,000 @ $14.41) |
| May 16, 2016 | William S Marth | President and CEO | Buy | $161K (12,500 @ $12.86) |
| May 13, 2016 | George Svokos | Chief Operating Officer | Buy | $160K (12,500 @ $12.82) |
| May 13, 2016 | Steven R Hagen | SVP Manufacturing & Pharmaceut | Sell | $30K (2,361 @ $12.77) |
| Nov 9, 2015 | Ambra Constance M D | 10% Owner | Sell | $980K (50,000 @ $19.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.